ArticleJournal of Korean Neurosurgical Society2026
Nintedanib Attenuates Epidural Fibrosis after Laminectomy in Rats.
Article in Journal of Korean Neurosurgical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveEpidural fibrosis (EF) is a major contributor to postoperative morbidity following laminectomy (LAM). This study investigated the antifibrotic, anti-inflammatory, and anti-angiogenic effects of nintedanib (NIN), a multi-tyrosine kinase inhibitor, in a rat model of post-LAM EF.
methodsTwenty-one male Wistar albino rats were assigned to three groups : control, LAM, and LAM + NIN. The LAM procedure was performed at the L3 level. NIN administration, following LAM, was administered orally at a dose of 50 mg/kg/day for 28 days. Histopathological evaluations included Hematoxylin & Eosin staining for dura mater thickness and fibroblast density, and Masson's trichrome staining for collagen deposition and adhesion grading. α-smooth muscle actin (α-SMA) expression was evaluated using immunohistochemistry and reverse transcription-quantitative polymerase chain reaction. Gene expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor (PDGFR), and transforming growth factor-β1 (TGF-β1) was quantified to characterize inflammatory, angiogenic, and fibrogenic responses. Statistical comparisons were conducted using one-way analysis of variance or Kruskal-Wallis tests with appropriate post hoc analyses.
resultsThe LAM group exhibited marked post-LAM changes, including increased dura mater thickness (8.20±0.23 vs. 3.93±0.08 μm in controls, p<0.0001), elevated fibroblast density (p=0.0006), severe collagen deposition, and high-grade epidural adhesions (grade 3, p=0.0006). NIN treatment attenuated these alterations, reducing dura mater thickness (4.80±0.20 μm; p<0.0001 vs. LAM), fibroblast density (p<0.01), and adhesion grade (grade 1, p=0.0012). α-SMA immunoreactivity was high in LAM (grade 3, p<0.0001), whereas NIN significantly suppressed myofibroblast activation (grade 1, p=0.0012). NIN also significantly downregulated inflammatory mediators TNF-α (p<0.001) and IL-1β (p<0.001), as well as angiogenic markers VEGF (p<0.001) and PDGFR (p<0.001), and fibrogenic mediators TGF-β1 (p<0.001) and α-SMA (p<0.01). These findings indicate that NIN suppresses fibroblast activation, extracellular matrix accumulation, and myofibroblast differentiation, thereby limiting epidural adhesion and scar maturation.
conclusionNintedanib effectively mitigated epidural fibrosis after LAM through combined antifibrotic, anti-inflammatory, and anti-angiogenic actions. By improving the dural structure and reducing key molecules that contribute to scar formation, NIN shows significant promise as a treatment to prevent postoperative epidural adhesions. Future studies with extended follow-up may help clarify its clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.